This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Abiomed's (ABMD) Preliminary Q3 Results Cheer Investors
by Zacks Equity Research
Abiomed (ABMD) raises its fiscal 2019 guidance. The company also expects to see strong contribution from its core Impella product line.
Here's Why Investors Should Hold Luminex (LMNX) Stock Now
by Zacks Equity Research
Luminex (LMNX) gains from strength in the Aries platform. However, cutthroat competition in the life sciences industry is worrisome.
The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance
The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance
The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance
4 Stocks That Had Massive Earnings Surprises in 2018
by Ankita Gupta
Given the market volatility, let's take a look at four stocks that survived the onslaught and even surpassed market expectations.
Zacks.com featured highlights include: Abercrombie & Fitch, Pacira Pharmaceuticals, Penumbra, Sprint and Salesforce.com
by Zacks Equity Research
Zacks.com featured highlights include: Abercrombie & Fitch, Pacira Pharmaceuticals, Penumbra, Sprint and Salesforce.com
OrthoPediatrics (KIDS) Catches Eye: Stock Jumps 10.3%
by Zacks Equity Research
OrthoPediatrics (KIDS) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
In Search of an Earnings Beat? Play These Top 5 Stocks
by Sanghamitra Saha
These top-ranked stocks may surpass bottom-line estimates in their next release.
Is Penumbra (PEN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (PEN) Outperforming Other Medical Stocks This Year?
Zacks.com featured highlights include: Papa Murphy's, Penumbra, Tesla, Ameren and Arbor Realty
by Zacks Equity Research
Zacks.com featured highlights include: Papa Murphy's, Penumbra, Tesla, Ameren and Arbor Realty
5 Low-Beta Stocks to Beat Market Volatility
by Zacks Equity Research
We have developed a strategy to show that securities with lower volatility than the market can generate lucrative returns.
Is Penumbra (PEN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (PEN) Outperforming Other Medical Stocks This Year?
DexCom (DXCM) Catches Eye: Stock Jumps 8.8%
by Zacks Equity Research
DexCom (DXCM) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Penumbra (PEN) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of 466.67% and 9.72%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Penumbra (PEN) Q3 Earnings Preview: What to Watch Ahead of the Release
by Zacks Equity Research
Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Penumbra (PEN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Penumbra (PEN) closed at $138.53, marking a +0.2% move from the previous day.
Is Penumbra (PEN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (PEN) Outperforming Other Medical Stocks This Year?
Penumbra (PEN) Stock Moves -1.17%: What You Should Know
by Zacks Equity Research
Penumbra (PEN) closed at $140.68 in the latest trading session, marking a -1.17% move from the prior day.
Penumbra (PEN) Stock Moves -1.9%: What You Should Know
by Zacks Equity Research
Penumbra (PEN) closed at $131 in the latest trading session, marking a -1.9% move from the prior day.
Top Stock Picks for the Week of October 8th
by Panel Of Zacks Experts
Two Technology Companies With Different Focus.
Accelerate Diagnostics (AXDX) Surges: Stock Moves 6% Higher
by Zacks Equity Research
Accelerate Diagnostics (AXDX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Zacks Market Edge Highlights: Intuitive Surgical, BioTelemetry, Edwards Lifesciences, Penumbra and Vericel
by Zacks Equity Research
Zacks Market Edge Highlights: Intuitive Surgical, BioTelemetry, Edwards Lifesciences, Penumbra and Vericel
How to Invest in the Hot Medical Device Innovators
by Tracey Ryniec
Forget the biotechs. Medical device companies are innovating in amazing ways. Here's how to invest.
Tandem Diabetes Care (TNDM) Catches Eye: Stock Jumps 7.4%
by Zacks Equity Research
Tandem Diabetes Care (TNDM) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.